Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 92
- Registration Number
- NCT00006066
- Locations
- ๐บ๐ธ
Nyu Ny Nichd Crs, New York, New York, United States
๐บ๐ธChildren's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States
๐บ๐ธUsc La Nichd Crs, Los Angeles, California, United States
Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-12-14
- Target Recruit Count
- 16
- Registration Number
- NCT00000875
- Locations
- ๐บ๐ธ
The Ctr For Blood Research Inc, Boston, Massachusetts, United States
The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 18
- Registration Number
- NCT00000986
- Locations
- ๐บ๐ธ
Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States
The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 72
- Registration Number
- NCT00000825
- Locations
- ๐บ๐ธ
Thomas Street Clinic C605-020 CRS, Houston, Texas, United States
A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 6
- Registration Number
- NCT00000680
- Locations
- ๐บ๐ธ
Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States
A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 104
- Registration Number
- NCT00000820
- Locations
- ๐บ๐ธ
Alabama Therapeutics CRS, Birmingham, Alabama, United States
๐บ๐ธUniversity of Colorado Hospital CRS, Aurora, Colorado, United States
๐บ๐ธSUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States
Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2015-05-15
- Target Recruit Count
- 42
- Registration Number
- NCT00001131
- Locations
- ๐บ๐ธ
Johns Hopkins Hosp, Baltimore, Maryland, United States
Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 100
- Registration Number
- NCT00006291
- Locations
- ๐บ๐ธ
Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States
๐บ๐ธAlabama Therapeutics CRS, Birmingham, Alabama, United States
๐บ๐ธUSC CRS, Los Angeles, California, United States
A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 36
- Registration Number
- NCT00000909
- Locations
- ๐ฌ๐ง
Kobler Ctr. of Chelsea Westminster Hosp. C604-030 CRS, London, United Kingdom
Effect of Interleukin-2 on HIV Treatment Interruption
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 80
- Registration Number
- NCT00015704
- Locations
- ๐บ๐ธ
UCLA CARE Center CRS, Los Angeles, California, United States
๐บ๐ธSan Mateo County AIDS Program, San Mateo, California, United States
๐บ๐ธSt. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.